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Abstract
Background: Trial registries were established to combat publication bias by creating a comprehensive and
unambiguous record of initiated clinical trials. However, the proliferation of registries and registration policies means
that a single trial may be registered multiple times (i.e., “duplicates”). Because unidentified duplicates threaten our
ability to identify trials unambiguously, we investigate to what degree duplicates have been identified across
registries globally.
Methods: We retrieved all records from the World Health Organization (WHO) International Clinical Trials Registry
Platform (ICTRP) search portal and made a list of all records identified as duplicates by the ICTRP. To investigate how to
discriminate duplicates from non-duplicates, we applied text-based similarity scoring to various registration fields of
both ICTRP-identified duplicates and arbitrary pairs of trials. We then used the best similarity measure to identify the
most similar pairs of records and manually assessed a random sample of pairs not identified as duplicates by the ICTRP
to estimate the number of previously unidentified (or “hidden”) duplicates.
Results: Two hundred eighty-five thousand unique records, or 271 thousand unique trials after accounting for known
duplicates, were retrieved from the ICTRP portal in April 2015. We found that the title field best discriminated duplicates
from non-duplicates. Out of 41 billion total pair-wise comparisons, we identified the 474,000 pairs of titles with the
highest similarity scores (> 0.5) . After manually assessing a random sample of 434 pairs, we estimated that 45 % of all
duplicate registrations currently go undetected and remain to be identified and confirmed as duplicates. Thus, the
actual number of unique trials represented in this dataset is estimated to be approximately 258,000 (5 % less).
Conclusions: The ICTRP portal does not currently enable the unambiguous identification of trials across registries.
Further research is needed to identify and verify the duplicates that currently go undetected. Sponsors, registries, and
the ICTRP should consider actions to ensure duplicate registrations are easily identifiable.
Keywords: Clinical trials, Trial registration, Duplicate registrations
Background
Prospective registration of clinical trials, a scientific and
ethical imperative, is required by various policies and laws
throughout the world [1–4]. A key goal of trial regis-
tration is to enable identification of all conducted and
ongoing trials relevant to a given topic. This goal can
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only be met if all relevant trials are registered, and the
search system can accurately identify them, thereby avoid-
ing both false positives and false negatives. Even when
these two conditions are met, however, it is possible
that duplicate registrations of the same study in one or
more registries could interfere with the ability to account
for all trials by making it impossible to determine how
many trials actually exist [5]. Duplicates can occur when
a trial sponsor purposefully registers their trial in more
than one registry, or when different people associated
with the trial (especially for multi-site, multi-national tri-
als) register the trial in an uncoordinated fashion. This
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problem was recognized by the World Health Organi-
zation (WHO) Mexico statement [6], which called for
“unambiguous identification” of each trial, and led to the
establishment of the International Clinical Trials Registry
Platform (ICTRP) by the WHO. The WHO also created
the Universal Trial Number (UTN) scheme to facilitate
the unambiguous identification of trials by allowing a
unique number to be associated with a trial throughout its
life cycle. Unambiguous identification is important both
to prevent double (or triple) counting of evidence in sys-
tematic reviews and meta-analyses and to ensure that all
registry records describing each relevant trial can be iden-
tified and retrieved. Registry data are also being used
to study the clinical research enterprize itself [7–9], and
duplicate registrations could skew the results of such stud-
ies. In addition, the unambiguous identification of trials is
an important step on the way to enhancing the efficiency
of systematic reviews using information technology [10].
If the different versions of the trial registration use the
same trial identifier (e.g., in the secondary ID field) and/or
use the same words to describe key trial attributes, then
it can be easy to detect. However, this is frequently not
the case. We have shown how some duplicates appear
quite different (e.g., different titles, sponsors, and condi-
tion terms), and some non-duplicates appear to describe
the same trial (e.g., same words for the title, sponsor,
and condition) [5]. ClinicalTrials.gov, the largest registry,
accepts trials from anywhere in the world. It takes steps to
avoid and detect possible duplicates; when identified, only
one version of the trial record is kept active. We are not
aware of the processes used by other registries to either
prevent or detect duplicate registrations.
In the following, we use record to refer to a trial as
registered in a specific registry, and variants to refer to dif-
ferent versions of a record within that registry (see Table 1
for an example). Most registries list a single authorita-
tive variant per record, but the European Union Clinical
Trials Register (EUCTR) contains a variant of the pro-
tocol information for each member state in which the
trial is registered. The ICTRP provides a consolidated
search portal that currently lists over 285,000 records
(over 320,000 variants) from 16 registries. Trials registered
in more than one registry (or more than once in the same
registry) would have more than one record in the ICTRP
data. Although the ICTRP identifies some pairs (or trip-
licates) as representing the same trial (known duplicates),
we have observed that they seem to not identify other
apparent duplicates as representing the same trial (hidden
duplicates). Systematic reviewers who use the ICTRP por-
tal in an attempt to find a complete list of all trials relevant
to their review would therefore unsure about how many
unique trials truly exist. This poses an additional prob-
lem to be solved during the review, and it could affect the
assessment of bias by inflating the number of trials that












A trial registered in both the European Union Clinical Trials Register (EUCTR) and
ClinicalTrials.gov illustrates the distinction we make between a trial, a record, and a
variant. A trial may have been registered in more than one registry, resulting in
multiple records. An EUCTR record may have been registered in multiple member
states, resulting in multiple variants of that record
did not publish results. While these problems are famil-
iar for those conducting systematic reviews based on the
scientific literature, registries should be able to provide a
solution. Unfortunately, the proliferation of trial registra-
tion policies and registries has created barriers to doing
this, despite the existence of the ICTRP portal [5]. We
conducted the present analysis to estimate the magnitude
of this problem and to recommend ways to improve this
situation.
Methods
We retrieved the complete ICTRP dataset in XML format
in April 2015 using a special arrangement set up by the
WHO. The ICTRP dataset contains the 20 items of the
WHO trial registration dataset [11], which includes the
registration ID, secondary IDs, public and scientific titles,
sponsors, contact information, conditions, interventions,
outcomes, inclusion criteria, and several other fields. We
removed HTML tags and clearly nonsensical secondary
IDs and imported the data into a relational database.
The data did not contain the record groupings (i.e., the
known duplicates) as displayed by the ICTRP search por-
tal. To reproduce the record groupings, we matched the
contents of the secondary ID field to record IDs by split-
ting the secondary ID into words (as separated by white
space or one of the characters “,; .”) and looking for a
matching record ID. For most registries, we looked for
an exact match, while for EUCTR we allowed the EUCTR
prefix and the country code (identifying a variant of the
record) to be absent. The public EUCTR system is rela-
tively new, but trials have been registered in the European
Clinical Trials Database (EudraCT) for over a decade,
so many references to records in the EUCTR lack the
EUCTR prefix. We created groups of records based on the
matched secondary IDs for all variants of each record and
considered each record in a group to be a known duplicate
of all other records in that group.
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To estimate the number of hidden duplicates, we
employed a two-stage strategy: scoring of pairs of records
based on a text-based similaritymeasure followed byman-
ual inspection of a random sample of highly scored pairs.
The similarity measure developed for the first stage need
not be truly predictive of a pair of records being dupli-
cates; it only needs to reduce the number of candidate
pairs sufficiently so that the second stage can be per-
formed efficiently. The similarity scoring thus acts as a
sieve that eliminates the vast majority of candidate pairs
while only eliminating a small proportion of duplicates.
This boosts the probability that a randomly selected pair
are true duplicates and thus reduces the number of record
pairs that have to be assessed manually.
To compute similarity scores, we normalized all the
text (converted it to lowercase Latin characters, digits,
and punctuation), tokenized it (separated it into individ-
ual words), and constructed a searchable index. When an
EUCTR record had multiple variants, we used the vari-
ant that was registered first. For redacted records (i.e.,
public title “N/A” in EUCTR, or “[Trial of device that is
not approved or cleared by the U.S. FDA]” in ClinicalTri-
als.gov), the similarity score was always set to zero. We
considered the “concatenated” title (a concatenation of the
public title, scientific title, and acronym, because these
were not used consistently between registries), condition,
intervention, outcome, and inclusion criteria fields [11].
Where these fields could occur multiple times, we sim-
ply concatenated their values. The mathematical details of
our similarity scoring method can be found in Additional
File 1 and are briefly summarized in the following. For
each field, we assigned a weight to eachword so that words
that rarely occur in that field received high weight and
words that occur frequently received low weight, using
inverse document frequency [12, 13]. We also gave zero
weight to stop words (e.g., “and” and “the”) and punctua-
tion. To allow for optimizations (see Additional file 1), we
did not assign greater weight to words that occurred more
than once. However, we did consider the occurrence of the
same word in different fields as two separate features. We
used cosine similarity [14] to score the similarity of two
records; a score of 0 means the records are completely dif-
ferent, and a score of 1 means the records contain exactly
the same set of words in the same fields.
We first investigated the properties of our similarity
scores to select the best fields for use in the final simi-
larity scoring of record pairs. To do this, we computed
similarity scores for all pair-wise comparisons between a
random sample of 7000 records, as well as between all
known duplicates. We computed scores for each field in
isolation, as well as an overall score. We selected the field
that resulted in the best discrimination between known
duplicates and general pair-wise comparisons. Then, we
computed and recorded similarity scores for all pairs of
records that had a similarity of 0.5 or above on the selected
field.
We drew random samples of pairs not known to be
duplicates of each other, with title similarity scores in spe-
cific ranges, starting with 0.9 − 1.0. We judged whether
each pair of records appeared to be duplicates of each
other, using the criteria described below. We estimated
the Binomial proportion and the corresponding Clopper-
Pearson confidence interval [15] of pairs that were iden-
tified as duplicates. From the proportion we computed
the estimated number of unidentified duplicates, which
we compared with the number of known duplicates to
compute the percentage of duplicates that remains hid-
den. We used the lower and upper bounds of the con-
fidence interval for the proportion in the same way to
compute a lower and upper bound for the percentage of
duplicates that remains hidden. After obtaining a suffi-
ciently accurate estimate for one interval, we would use
the estimated percentage hidden to estimate the propor-
tion of pairs that could be expected to be duplicates in
the next interval (i.e., 0.8 − 0.9, then 0.7 − 0.8, etc.). We
decided whether to continue the analysis based on the
sample size that would be required to get an accurate esti-
mate of the percentage of hidden duplicates in the next
interval.
Pairs of records were determined to be likely dupli-
cates or non-duplicates using a web interface that showed
two records side-by-side (Fig. 1). Rating was performed
by the first author, who has research experience in meta-
analysis and systematic review and detailed knowledge of
registry systems and data. Difficult cases were discussed
with co-authors and colleagues at ClinicalTrials.gov. The
summary protocol information provided in the records
are not sufficiently detailed to allow for the identification
of duplicates with certainty. Therefore, we used a number
of signals to determine the most likely answer. If the titles
were nearly identical but contained clearly contradictory
phrases (e.g., “fed conditions” versus “fasting conditions”),
the trials were judged to be non-duplicates. If the trials
shared a sponsor and had two identical secondary IDs that
were not US federal grant numbers (which often apply to
many different trials) and that were not likely to occur
by chance (i.e., longer than five characters or digits), we
judged the trials to be (hidden) duplicates. On the other
hand, if the trials shared a sponsor and had different sec-
ondary IDs in the same format, we judged them to be
different. Absent such cues, similarity of the titles, con-
ditions, interventions, inclusion criteria, and outcomes
were judged. As each registry has different requirements
and quality assurance processes, the format and level of
detail of these fields vary greatly between registries, so
no objective criterion could be formulated. If these fields
were sufficiently similar and the study start and end dates,
sponsors, and investigators were not contradictory, the
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Fig. 1 Record comparison user interface. Records were compared using a simple web application that shows two records side-by-side. The rater
could use the “Same trial,” “Don’t know,” and “Different” buttons to indicate their judgment and proceed to the next pair by clicking “Next”. Mistakes
could be corrected by simply clicking the correct button afterwards
records were judged to be (hidden) duplicates. However,
in case of doubt they would be judged non-duplicates.
We followed ClinicalTrials.gov policy regarding follow-on
studies: if an extension phase was part of the original pro-
tocol, it would be considered part of the same trial, but if
an extension phase was set up post hoc under a new pro-
tocol, it was considered a new trial [16]. Such extensions
entail additional data collection on some or all of the origi-
nal trial’s population after it was planned to end and could
involve alternative or additional interventions. We are not
aware of the policies other registries have in this area but
have observed that separately registered extension studies
are also quite common in the EU Clinical Trials Register.
Identifying extension studies and other interrelationships
between studies might be valuable but is essentially a dif-
ferent research question that would shift the focus from
a between registry problem to a within registry problem.
Therefore, in our analysis, separately registered extension
studies were not considered duplicates of the original trial.
Data processing programs were implemented in the
Clojure programming language, and we imported the data
into a MySQL database. Similarity scoring was imple-
mented in a Java program using the ClinicalTrials.gov
search engine “SE4” [17]. Records were compared using
a small web application (shown in Fig. 1) using a Clo-
jure server and an HTML/JavaScript frontend. Statistical
analyses were carried out in the R statistical software. Full
source code [18] is available from the Zenodo platform for
sharing research outputs.
Results
A total of 320,790 variants were retrieved from the WHO
ICTRP portal, representing 285,177 unique records from
16 registries. The full dataset is available from Zenodo
[19]. The five largest registries were as follows: Clinical-
Trials.gov (187,554 records, 66 %), the EU Clinical Trials
Register (25,179 records, 9 %), the Japanese Primary Reg-
istries Network (18,444 records, 6 %), ISRCTN (13,340
records, 5 %), and the Australian New Zealand Clinical
Trials Registry (10,358 records, 4 %).
The dataset contained 387,264 secondary IDs, of which
55,206 could be matched to the registry ID of one of the
records in the ICTRP dataset. In total, 26,201 records
(9 %) had at least one known duplicate, reducing the
assumed number of unique trials by 13,897 to 271,280.
There were 10,932 groups of two records and 1372 groups
of three or more records; the largest group contained ten
records. Most duplicates occurred between registries, as
only 55 groups of two or more records occurred within
a single registry. However, the maximum number of reg-
istries in any group was five, and 111 groups had records
in four or five registries.
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The initial analysis showed that similarity scores
between arbitrary pairs of records were highly concen-
trated near zero, regardless of the field that was chosen.
Figure 2 illustrates this for the overall similarity scores
for arbitrary pairs of records and contrasts it with over-
all scores for the known duplicates. Figure 3 shows the
score distribution for the 15,805 pairs of known dupli-
cates for the overall score and each of the five fields.
Because the title field resulted in the best discrimination
between duplicates and non-duplicates, it was used in all
subsequent analyses. The median title similarity score for
known duplicates was 0.86 (IQR 0.71–0.96), and 90 % of
all known duplicates had a score exceeding 0.5.
We identified all pairs of records with a title similar-
ity score of 0.5 or greater. There are 41 billion pair-wise
comparisons between all records, of which 474,000 had a
score of 0.5 or greater. Using an optimization described
in Additional file 1, we needed to calculate only 206 mil-
lion comparisons, which took 6 h on a desktop computer
with an Intel Core i7-4790 Quad Core processor and 8 GB
RAM.
The results are shown in Fig. 4: there are a large num-
ber of records with highly similar titles that are not known
to be duplicates of each other. We estimated the pro-
portion of those pairs that are in fact duplicates for the
ranges 0.9 − 1.0, 0.8 − 0.9, and 0.7 − 0.8, covering 76 % of
known duplicates. In total, 434 pairs were assessed, with
the number assessed in each interval selected based on the
width of the 95 % confidence interval for the percentage
of duplicates that remain hidden. The results are shown
in Table 2 and Fig. 5. For the score range 0.9 − 1.0, 43 %
of assessed pairs were likely duplicates, for 0.8 − 0.9
this was 13 %, and for 0.7 − 0.8 it was 5.6 %. These
numbers correspond to respectively 48, 39, and 47 % of
duplicate registrations remaining unidentified. Overall, it
appears that only about 55 % of duplicates have been
identified in the ICTRP portal. In the 0.6 − 0.7 simi-
larity score range, we expected only 1.1 % of sampled
pairs to be duplicates. To bound that value between 0.5
and 2.6 % (corresponding to 25 and 65 % hidden dupli-
cates, respectively) would require a sample size of 800
pairs. Therefore, we did not continue the analysis into the
0.6 − 0.7 range.
Discussion
Our analysis shows that the actual number of duplicates
in the ICTRP dataset could be twice as high as the num-
ber currently identified as duplicates by the ICTRP. This
would correspond to a reduction of the number of unique
trials in the ICTRP dataset from 271,000 records currently
to 258,000 actually unique studies (5 % less).
Recommendations for systematic reviewers
Systematic reviewers cannot afford to ignore registry
data when conducting systematic reviews [20], because
registry data is key to determining how many studies
have been done and how many have not published
their results. Therefore, registries should be consid-
ered as part of the search strategy for any review.
Reviewers will have to weigh the cost and benefit
of using the ICTRP portal and/or individual reg-
istries, and future research should investigate the pre-
cision and recall of various strategies to aid such
decisions.
Systematic reviewers need to be aware of the limitations
of the ICTRP portal and the individual registries. In the
ICTRP portal, any moderately large set of search results
is likely to contain some duplicate records that have not
been identified as such. Therefore, de-duplication remains
necessary, even for trials retrieved from registries. Fortu-
nately, the process is no different from identifying dupli-
cate publications of the same trial. The ICTRP does not
collect all data reported in the individual registries, so
after the initial screening phase we recommend that the
full record should be retrieved from the original reg-
istry. For example, ClinicalTrials.gov includes references
to publications, which can help to link registry records to
publications.
Fig. 2 Comparing the similarity scores of arbitrary pair-wise comparisons to those of known duplicates. Histogram of the overall (combined) similarity
scores of pair-wise comparisons between a random sample of 7000 records (left) compared to the similarity scores of known duplicates (right)
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Fig. 3 Distribution of similarity scores for known duplicates. Each panel is a histogram of the similarity scores for the population of known duplicates
on one of the five considered fields or the overall (combined) score
Recommendations for sponsors
We suggest that sponsors internally designate a single
registry record as their primary record, and refer to it con-
sistently as a secondary ID on all other records. This will
ensure proper grouping in the ICTRP search portal and
will enable systematic reviewers and other researchers to
easily identify duplicate registrations. Owing to the fact
that the secondary ID field does not provide the con-
text required to interpret other secondary IDs, linking all
registry records to an internal protocol ID is not suffi-
cient. Sponsors should focus their efforts on keeping the
primary record up-to-date; it could serve as the source
material for periodic updates to secondary records.
Recommendations for registries
Registries could be more proactive in eliciting other reg-
istry IDs from sponsors, for example by targeted questions
based on registered study locations (e.g., a drug trial with
a site in the EU would suggest that a record exists in the
EUCTR). Registries could also link to records in other
registries based on duplicates identified by the ICTRP,
similar to how ClinicalTrials.gov displays publications
identified by PubMed [21]. Unfortunately, the ICTRP por-
tal does not currently allow a trial’s identified duplicates
to be retrieved. We also recommend that registries enact
policies and quality assurance processes to improve the
quality of published records. For example, issues such
as nonsense secondary IDs and multiple values per field
should be minimized. In addition, given that clinical trials
are increasingly international [22, 23], it would be ideal if
registries could allow sponsors to update their secondary
records by downloading the primary one from another
registry.
It is unfortunate that each EUCTR record has a (poten-
tially large) number of variants. We hope that the EUCTR
will start offering a single authoritative variant for each
record to the ICTRP in the future. That would remove a
layer of complexity for anyone using the ICTRP data.
Recommendations to the ICTRP
We believe significant benefit to clinical research could be
achieved by making the ICTRP dataset more readily avail-
able, for example by publishing electronic snapshots of the
full dataset at regular intervals. If the data were publicly
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Fig. 4 Known duplicates among highly similar records. Highly similar pairs (light gray) and the fraction that are known duplicates (dark gray). Pairs
with similarity between 0.5 and 0.6 were identified but are not shown due to their large number (64 % of all pairs with a score over 0.5)
available, third parties could improve the data in various
ways, e.g., by standardizing fields between registries and
mapping free text to controlled vocabularies.
The ICTRP portal is currently only accessible through
a web browser. If other computer systems could execute
queries and retrieve specific records in XML format, other
services that deal with clinical trials would benefit. For
example, the primary registries could more easily link
back to the ICTRP portal, or directly to duplicate records
in other registries. The ICTRP portal could also function
as a linking hub for journal articles that refer to registry
IDs. The ICTRP should play a central role in the inter-
national registry system, but given the current state of
affairs, it is sometimes ignored. Instead, major studies
using registry data have focussed their efforts on using
ClinicalTrials.gov [7–9, 24–27], even though its coverage
of trials conducted worldwide is not as comprehensive as
that of the ICTRP portal.
The ICTRP dataset lacks standardization in some areas;
date formats are inconsistently used, for example. The
Table 2 The estimated number of unknown duplicates based on
a random sample from each title similarity score range.
Confidence intervals for the percentage of hidden duplicates
based on the exact binomial confidence interval for the
proportion of duplicates in the sample
Score range D. in sample D. known D. unknown (est.) % hidden
0.7 < x ≤ 0.8 7 / 125 (5.6 %) 2194 1957 47 (26–64)
0.8 < x ≤ 0.9 13 / 100 (13 %) 3489 2265 39 (26–51)
0.9 < x ≤ 1.0 89 / 209 (43 %) 5805 5393 48 (44–52)
ICTRP should work with registries to further standard-
ize how fields are reported and should communicate to
data consumers what standards have been established.
Addressing the issues of duplicate registrations and diver-
gent reporting will only become more challenging as
the number of independent registries grows. Therefore,
the ICTRP should aim to limit the number of new reg-
istries, and instead focus on increasing the use of existing
registries.
Fig. 5 Estimated number of unknown duplicates. The number of
unknown duplicates estimated by randomly sampling from the pairs
of records that are not known to be duplicates. The investigated range
of title similarity scores (0.7–1.0) contains 76 % of all known duplicates
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Reflections on the secondary ID field
The secondary ID field has proven to be useful in allowing
some records to be grouped in the ICTRP search results.
The ICTRP does this by matching secondary IDs to the
registry IDs of known records. There are good reasons
why it does not match other secondary IDs, however. The
secondary ID field has been used to enter many differ-
ent kinds of identifiers that may not uniquely identify a
trial, and there is no information to indicate what kind
of identifier has been entered. For example, grant num-
bers are commonly entered, and the most common grant
number occurred on 262 separate trial records. Nonsense
values such as “Version 1” and “Nil known” are also com-
mon. It is especially puzzling that occasionally multiple
IDs are entered in a single secondary ID field, because all
registries allow multiple secondary ID fields to be used.
Matching secondary IDs alone is also risky because differ-
ent sponsors may use overlapping identifier schemes, with
the use of incrementing integers being the most common.
Despite these issues, it must be possible to extract some
additional value from the secondary ID field. We per-
formed two small experiments to illustrate this. First,
we took all secondary IDs that matched the WHO
UTN identifier format. Surprisingly, the ICTRP portal
does not appear to group trials by UTN (for example,
DRKS00005274 and NCT02139163 both have the UTN
U1111-1147-8393, but are not grouped in the search
results). In total, 2058UTNswere found, which resulted in
151matchings between trials, 56 of which were previously
unknown. Second, we harvested a list of 6750 trial iden-
tifiers from the GlaxoSmithKline study register (http://
www.gsk-clinicalstudyregister.com/) and matched these
to secondary IDs on studies where GlaxoSmithKline was
listed as a sponsor (we matched 123 variants of the Glax-
oSmithKline name). We found 4270 matching secondary
IDs, which would result in 423 newly identified duplicates
and reduce the number of registered GlaxoSmithKline tri-
als by 6 %. Based on these two experiments, we believe
that a significant number of hidden duplicates could be
identified by using similar strategies based on secondary
IDs with external corroborating evidence. However, such
work should include an assessment of the false positive
rate.
Limitations
Our work has a number of limitations. Most importantly,
we provide a rough estimate of the number of hidden
duplicates, but do not identify what those duplicates are;
our similarity measure is not specific enough to allow effi-
cient identification of all hidden duplicates. Our estimate
of the number of duplicates depended on a somewhat
subjective manual assessment of whether two records rep-
resented the same trial, which we attempted to fortify
by setting clear criteria. The reliability of our estimates
could be increased by using multiple raters, but given
the exploratory nature of this study, we used a single
rater only. We also did not consider that some of the
duplicates identified by the ICTRP could be false posi-
tives. The similarity scores were calculated in a simple
way, and more advanced methods (e.g., machine learn-
ing) could improve the ability to discriminate duplicates
and non-duplicates, which would allow a more precise
estimate. However, a more precise estimate would be of
questionable value, and adopting more advanced methods
would have greatly increased research effort and com-
putation times. Advanced methods also have their own
issues, such as the potential for over-fitting to the data
and reduced transparency of the results. In estimating the
number of hidden duplicates, we assumed that the prob-
ability of a duplicate being hidden does not depend on its
similarity score. Our analysis of the most similar records
(covering 76 % of known duplicates) did not suggest that
such a dependency exists, but if it does, we may have
underestimated the number of hidden duplicates.We can-
not rule out that such confounding exists, for example
because well-coordinated sponsors might be more likely
to both register using similar titles and link their records
using secondary IDs. In any case, our conclusion that a
large proportion of duplicates remain undetected would
remain valid, even if the actual proportion might turn
out to be somewhat larger. Another limitation is that
we used the first registered variant to represent EUCTR
records. In rare cases, some variants are in languages
other than English, or are simply incomplete (presum-
ably because a more complete variant exists). Handling of
EUCTR records could therefore be improved by employ-
ing a language identification technique to preferentially
select English language variants, as well as by selecting the
most complete variant (though defining “most complete”
could prove a challenge).
Our study is also limited by the quality of the ICTRP
dataset, which draws from 16 disparate registries. Report-
ing patterns and quality vary greatly between registries,
and few fields have standardized values. For example,
a number of different date formats is in use, and date
formats differ both between registries and between the
various date fields within registries. All of the registries
have different policies regarding the specific informa-
tion that goes into each field. For example, the EUCTR,
which only includes drug trials, has very structured infor-
mation on interventions, with labeled sub-fields for dif-
ferent compound names (brand, product, and generic),
the pharmaceutical form, and the dosing regimen. By
contrast, ClinicalTrials.gov, which includes studies of all
intervention types, requires the specification of the inter-
vention types (behavioral, drug, device, etc.) as well as
textual descriptions of the interventions. On the other
hand, ClinicalTrials.gov has quality assurance in place
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that encourages specific descriptions of outcome mea-
sures [16], so there tends to be more information on
outcome measures in ClinicalTrials.gov than in other reg-
istries. This partly explains the poor similarity of known
duplicates on the conditions, interventions, outcomes,
and inclusion criterion fields (see Fig. 4).
Conclusions
Our analysis shows that approximately 45 % of all dupli-
cate registrations currently go undetected. A concerted
effort by policy makers, registries, and trial sponsors is
needed to ensure that the unambiguous identification of
trials is possible. We also call for snapshots of the com-
plete WHO ICTRP dataset to be made publicly available
for use by independent research groups, so that this chal-
lenge and other research questions can be addressed.
Additional file
Additional file 1: Similarity scoring method. A PDF document containing
the mathematical details of our similarity scoring method. (PDF 125 kb)
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